Medical Oncology — Medicare Part B billing by state
28 physician groups whose primary specialty is Medical Oncology billed $0.10B to Medicare fee-for-service in 2024.
Calendar year 2024 · Medicare fee-for-service Part B
| State | Groups | Services | Beneficiary-episodes | Medicare payments | Standardized payments ↓ | Payments / group | Services / group |
|---|---|---|---|---|---|---|---|
| Alabama | 3 | 1,461,282 | 84,963 | $26,515,000 | $27,327,622 | $8,838,333 | 487,094 |
| North Dakota | 1 | 630,049 | 7,420 | $8,771,743 | $8,617,022 | $8,771,743 | 630,049 |
| Texas | 4 | 647,795 | 23,996 | $8,491,784 | $8,518,996 | $2,122,946 | 161,949 |
| Arizona | 1 | 408,677 | 14,623 | $7,622,359 | $7,648,331 | $7,622,359 | 408,677 |
| Massachusetts | 3 | 95,225 | 54,182 | $7,895,321 | $7,355,299 | $2,631,774 | 31,742 |
| Pennsylvania | 5 | 753,479 | 28,144 | $7,127,261 | $7,239,362 | $1,425,452 | 150,696 |
| California | 5 | 292,165 | 11,858 | $6,268,103 | $5,903,826 | $1,253,621 | 58,433 |
| New Jersey | 2 | 215,911 | 7,643 | $5,073,223 | $4,923,929 | $2,536,612 | 107,956 |
| Utah | 1 | 352,443 | 27,652 | $4,219,475 | $4,303,960 | $4,219,475 | 352,443 |
| Tennessee | 1 | 156,257 | 8,434 | $3,345,937 | $3,373,133 | $3,345,937 | 156,257 |
| Indiana | 1 | 324,648 | 11,887 | $3,105,632 | $3,180,428 | $3,105,632 | 324,648 |
| New York | 4 | 35,377 | 15,961 | $3,104,410 | $2,753,166 | $776,102 | 8,844 |
| Florida | 3 | 308,685 | 9,512 | $2,711,317 | $2,667,854 | $903,772 | 102,895 |
| Nebraska | 1 | 128,868 | 7,465 | $2,024,380 | $2,057,324 | $2,024,380 | 128,868 |
| Maryland | 4 | 28,165 | 22,013 | $1,329,765 | $1,234,952 | $332,441 | 7,041 |
| District of Columbia | 1 | 4,416 | 2,589 | $346,461 | $311,332 | $346,461 | 4,416 |
| Michigan | 1 | 32,845 | 1,663 | $304,613 | $310,268 | $304,613 | 32,845 |
| New Hampshire | 1 | 1,886 | 1,001 | $130,507 | $128,580 | $130,507 | 1,886 |
| Colorado | 1 | 1,003 | 475 | $110,012 | $109,065 | $110,012 | 1,003 |
| Connecticut | 2 | 1,491 | 796 | $116,365 | $106,942 | $58,183 | 746 |
| Minnesota | 2 | 2,900 | 614 | $90,075 | $90,898 | $45,037 | 1,450 |
| Rhode Island | 1 | 571 | 347 | $60,321 | $56,961 | $60,321 | 571 |
| Oregon | 1 | 550 | 212 | $34,819 | $29,689 | $34,819 | 550 |
| North Carolina | 1 | 239 | 121 | $18,015 | $19,050 | $18,015 | 239 |
| Maine | 1 | 216 | 152 | $12,894 | $13,450 | $12,894 | 216 |
| Vermont | 1 | 110 | 87 | $4,926 | $5,508 | $4,926 | 110 |
| Ohio | 1 | 12 | 11 | $947 | $944 | $947 | 12 |
Need this specialty's market in one document?
Notify me at launchEach group carries one specialty label — the specialty most common among its clinicians in CMS's Doctors and Clinicians register — so every figure on this page counts groups, not individual clinicians. An organization's entire Medicare billing is credited to that one label, so a specialty's totals reflect how organizations are labeled, not the specialty of each service; large multi-specialty organizations — where no single specialty is a majority of the clinicians — account for much of the volume shown under many specialties. Totals include only volume that can be credited to a single group; clinicians registered with more than one group are left out of group totals and shown as “—” elsewhere on Nevvi. Clinicians not registered with any group, and groups without a specialty label, are also not included. A group is counted in every state its clinicians bill Medicare from, so state figures overlap and never sum to the national figure.
All figures are Medicare fee-for-service Part B only; Medicare Advantage claims are not included. Cross-state comparisons use standardized payments, which remove regional differences in what Medicare pays; services without a standardized amount — mainly Part B drugs — are not in that column, and the Medicare payments column shows what Medicare actually paid. Beneficiary counts are beneficiary-episodes: one person treated in more than one setting or state is counted in each.
Top codes by Medicare payments CY2024
| Code | Services | Medicare payments ↓ | Largest state markets |
|---|---|---|---|
| J9271 · Injection, pembrolizumab, 1 mg | 605,669 | $26,409,390 | ALNDTXAZMA |
| 99214 · Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 122,259 | $10,141,806 | ALNDTXAZMA |
| J0897 · Injection, denosumab, 1 mg | 425,222 | $8,603,751 | ALNDTXAZMA |
| 99215 · Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more | 42,568 | $5,039,250 | ALNDTXAZMA |
| 99213 · Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 48,215 | $2,798,035 | ALNDTXAZMA |
| J9144 · Injection, daratumumab, 10 mg and hyaluronidase-fihj | 70,920 | $2,790,472 | ALNDTXAZMA |
| 78815 · Nuclear medicine study from skull base to mid-thigh with ct scan | 1,917 | $2,384,132 | ALNDTXAZMA |
| 96413 · Administration of chemotherapy into vein, 1 hour or less | 23,821 | $2,282,413 | ALNDTXAZMA |
| G6015 · Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 7,387 | $2,020,009 | ALNDTXAZMA |
| J1459 · Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 49,510 | $1,849,016 | ALNDTXAZMA |
| J1439 · Injection, ferric carboxymaltose, 1 mg top by services | 1,050,000 | $909,931 | ALNDTXAZMA |
| J0881 · Injection, darbepoetin alfa, 1 microgram (non-esrd use) top by services | 323,590 | $749,438 | ALNDTXAZMA |
| J0185 · Injection, aprepitant, 1 mg top by services | 168,881 | $222,697 | ALNDTXAZMA |
| Q0138 · Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) top by services | 626,280 | $170,720 | ALNDTXAZMA |
| J1756 · Injection, iron sucrose, 1 mg top by services | 245,300 | $42,263 | ALNDTXAZMA |
| J1453 · Injection, fosaprepitant, 1 mg top by services | 149,700 | $16,533 | ALNDTXAZMA |
| J1100 · Injection, dexamethasone sodium phosphate, 1 mg top by services | 162,679 | $14,309 | ALNDTXAZMA |
| Q9967 · Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml top by services | 138,948 | $14,127 | ALNDTXAZMA |
Every code above is searchable free at full depth. Ranking organizations across several codes at once — one combined market view — is part of a Nevvi subscription.
Notify me at launch